Description: Savings from biosimilars have accelerated significantly in the past few years. There has been a number of relatively recent biosimilar launches that can help to shape our expectations of the financial impact that could result from this year’s big event. Savings from biosimilars have accelerated significantly in the past few years. There has been a number of relatively recent biosimilar launches that can help to shape our expectations of the financial impact that could result from this year’s big event.

Description: Evaluating the success of Disease Management Programs by looking at ROI and the risk management economic model. Issue No. 46.

Description: Discussion on Ebola, how it spreads and whether or not it is an epidemic or pandemic.

Description: This article explores telemedicine's impact on the health care system, health care costs, and actuarial pricing.

Description: Feature article featuring expert opinions on the future of health care

Description: Letter from the Editor - Mary van der Heijde

Description: Discussion and Opinion on how randomness affects measurement of provider contracting risk-sharing agreements

Description: This article outlines and summarizes research from Swiss Re about the prevalence of the Health Protection Gap throughout Asia, with a particular focus on China. Authors Robert Burr and David Zhang share key statistics on the scope of the gap, which is more than 800Bn USD in China alone, and discuss the role that technology and private-public partnership can play in reducing this gap over time. Readers will come away with an understanding of the scale of the problem within the Asia region as well as new ideas on how to solve similar problems within their own region.

Description: This article on IPV focuses on IPV during the COVID-19 pandemic

Description: The coming wave of biosimilars could dramatically affect prescription drug costs and benefit strategies over the next several years. The launch of many Humira biosimilars in 2023 is the Big Event that will largely determine the impact of the biosimilar wave. Payers have many decisions to make about coverage and formulary tiers. What factors will drive payer decision-making?